Please visit us at ENDOExpo 2024 (Booth 626)

NEW DATA: A Real-world Observational Study Fully Supports Test Performance

The addition of microRNA expression testing increases the sensitivity and specificity to detect thyroid cancer in pediatric patients

ATA 2019 Chicago, IL

Thyroid cancer is the most common endocrine malignancy, and incidence is rising. MAP kinase (MAPK) signaling has been implicated in playing a critical role in the initiation and maintenance of thyroid cancer, as evidenced by the high incidence of non-overlapping mutations of the genes encoding RET and TRK, as well as of NRAS, HRAS, KRAS, and BRAF. Although pediatric and adult thyroid cancers have been found to share many of the same driver mutations, it is not yet known and validated in pediatric populations whether molecular testing can improve diagnostic accuracy, particularly in ruling out malignancy. Further, it is not yet clear in pediatric populations whether microRNA expression can improve diagnostic accuracy. We sought to determine whether a 10-microRNA classifier developed and optimized for adult thyroid lesions could improve the diagnostic accuracy of thyroid nodules in pediatric patients. In future studies we plan to use these preliminary findings to further understand the molecular differences that drive the differential pathogenesis of pediatric versus adult tumors, despite sharing identical driving mutations.

Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.